





: Network

Neuromuscular Diseases (ERN EURO-NMD)

Patient reported outcome measures PROMMY the new app in the PROMs' ecosystem

Michelangelo Mancuso, MD, PhD, Prof. Azienda Ospedaliera Universitaria Pisana, Pisa (Italy)





ERN EURO-NMD

- o EURO-NMD includes 84 healthcare entities from 25 EU Member State
- o An estimated number of 100,000 patients with rare neuromuscular diseases is followed every year
- Over 200 different forms of NMDs frequently with multi-system involvement
- Multiple symptoms (i.e. muscle weakness, muscle pain, fatigue, difficulties in swallowing and breathing, sleeping problems....), not in the clinical registry
- Not only neuromuscular involvement....

There are some symptoms that have a critical impact on patient's daily life >
"Patients' symptom burden"


How will we manage those challenges?





Treatment effects

Genetic rel'ships





Looking at the future


- Al and ML in NMDs
- Digital Health Technologies (DHTs)
- NMDs specific OMs?
- NMDs specific PROMs?
- Digital biomarkers?
- Telemedicine



Al and DHTs in neurology







ML & Digital Health Technologies in clinical care



Clinical care: To improve the efficiency and efficacy of disease management



Providing earlier diagnoses & delivering more useful clinical phenotyping for prognostication



Enabling greater precision and more personalization of treatment



Monitoring response to treatment and disease trajectory



Motivating and engaging patients in their care and in their environment


Digital biomarkers

Can patient-generated health data from wearable and other mobile/electronic devices supplement or even replace study visits and their associated traditional data collection?




Patient Reported Outcome Measure(s)


PROMs deal with aspects of health that cannot be observed objectively and can therefore only be measured by asking the patient, for example, symptoms or complaints such as pain or mood disorders, and work, sport or housekeeping performances





Al in clinical research: focus on PROMs





Overall, the use of PROMs in the function and assessment of Al health technologies is not only possible, but is a powerful way of showing that, even in the most technologically advanced health-care systems, patients' perspectives remain central.



Electronic PROMs

Advances:

- Increased completion rates. In the case of surveys that are to be completed when the patient is at home, and not in hospital, there is an added benefit that electronic PROMs don't need to be posted back to the clinician or researcher
- Easy to remind participants to complete surveys (i.e. pop-up)
- Less risk of secondary data entry errors and more accurate and complete data

Why do we need PROMs and a NMD PROM?

• There is no PROM that uses a unique cross-sectional approach to accumulate information about the sumptomatology of patients with

Journal of Neuromuscular Diseases 11 (2024) 567–577 DOI 10.3233/JND-240003 IOS Press

Review

Patient-Reported Outcome Measures in Neuromuscular Diseases: A Scoping Review

Nicoline Voet^{a,b,1,*}, Ronne Pater^{a,b,1}, Joana Garmendia^c, Andone Sistiaga^c, Garazi Labayru^c, Benjamin Gallais^d, Ingrid de Groot^{e,1}, Samar Muslemani^f, Cynthia Gagnon^f and Christopher Graham^g

Abstract. Patient-reported outcome measures (PROMs) are valuable in comprehensively understanding patients' health experiences and informing healthcare decisions in research and clinical care without clinicians' input. Until now, no central resource containing information on all PROMS in neuromuscular diseases (NMD) is available, hindering the comparison and choice of PROMs used to monitor NMDs and appropriately reflect the patient's voice. This scoping review aimed to present a comprehensive assessment of the existing literature on using PROMs in children and adults with NMD. A scoping methodology was followed using Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) and COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN)

guidelines to assess the literature on PROMs in NMDs. Eligibility criteria encompassed articles describing psychometric development or evaluation of generic or disease-specific PROM-based instruments for adults and children with specific NMDs. The data charting process involved extracting measurement properties of included PROMs, comprising validity, reliability, responsiveness, and interpretability information. The review identified 190 PROMs evaluated across 247 studies

assessed. Validity was the most frequently investigated measurement property, with a limited number of PROMs sufficiently evaluated for a range of psychometric characteristics. There is a strong need for further research on the responsiveness and

in individuals with NMDs. The majority of PROMs were disease specific. The physical functioning domain was most

/rehab)

interpretability of PROMs and the development of PROMs on social functioning in NMD.

provement of diagnostics, therapies, se natural history

^aKlimmendaal, Rehabilitation Center, Arnhem, The Netherlands

^bDepartment of Rehabilitation, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands

^cDepartment of Clinical and Health Psychology and Research Methodology; Psychology Faculty, University of the Basque Country (UPV/EHU), Donostia-San Sebastián, Gipuzkoa, Spain

dÉCOBES, research and transfer, Cégep de Jonquière, Jonquière, Canada

ePatient association Spierziekten Nederland, Baarn, The Netherlands

^fMedicine & Health Sciences Faculty, Université de Sherbrooke, Quebec, Canada; CR-CHUS and CIUSSS Saguenay–Lac-St-Jean research centres, Québec, Canada

^gDepartment of Psychological Sciences and Health, University of Strathclyde, Scotland

WP7 parallel projects

- Development of a PROM for the most bothersome symptoms in

patients with NMD

- Development of the APP for patients engagement





PROJECT PLAN

Starting point: shich one is the most critical symptom for NMD patients?

How do we get this information from patients?

List of NMD symptoms (28), developed with PAGs and the ERN ExeC

LIST OF SYMPTOMS

- 1) Muscle fatigue
- 2) Mental fatigue
- 3) Muscle weakness
- 4) Muscle stiffness
- 5) Coordination e/o unbalance problems
- 6) Muscle pain
- 7) Impaired physical function/activity
- 8) Joint pain and/or swollen joints
- 9) Symptoms suggestive of cardiac impairment
- 10) Involuntary muscle contraction
- 11)Neuropathic pain
- 12)Vision impairment
- 13) Hearing impairment
- 14) Chewing and swallowing difficulties

- 15) Breathing difficulties
- 16) Speech problems
- 17) Headache
- 18) Cognitive impairment
- 19) Mental health issues
- 20) Behavioural impairment
- 21) Tingling and/or numbness
- 22) Dizziness
- 23) Sleep disturbance
- 24) Sexual dysfunction
- 25) Gastrointestinal dysfunction
- 26) Urinary dysfunction
- 27) Subjective sensory loss or extreme sensitivity to touch, temperature
- and/or pain
- 28) Autonomic symptoms



EURO-NMD

Building bridges and breaking barriers in rare neuromuscular diseases

Network Neuromuscular Diseases (ERN EURO-NMD)

ERN NMD PROM FOR ADULTS

Welcome to the Assessment of the Neuromuscular Disease (NMD) patients' symptom burden

Thank you for participating in our survey. Your feedback is important.

This survey will allow us to better identify your symptom burden! This survey is only for adult patients (18 years and older)! The survey must be completed by the patient only! If you are not able to complete it, please ask help to your caregiver! Data protection. This is an anonymous survey. We are not collecting any personal data and we will not share or make public information that can link you to individual responses presented in our final report. Please continue the survey if you agree on that thank you

SURVEY – ERN-NMD FOR ADULTS

- Survey in English and Italian
- General information: Gender, age-range, country, name of disease
- List of 28 symptoms with their explanation and a severity scale

	ou should provide an answer to all queries, quantifying how much a specific symptom (o
a group of syr	nptoms) is affecting your daily life
* 5. Muscle	Fatigue (i.e., overwhelming sense of tiredness, lack of energy and feeling exhausted)
O (None)	
O1(Mild)	
	te)
O 2 (Modera	

• 1108 answered obtained for all NMDs

LIST OF PATHOLOGIES

Have you been diagnosed with one of the following diseases?

Mitochondrial Diseases	Amyotrophic Lateral Sclerosis and other motor neuron diseases (excluding SMA)		
O Duchenne or Becker Muscular Dystrophy	O Spinal Muscular Atrophy (SMA)		
Facioscapulohumeral Muscular Dystrophy (FSHD)	O Myasthenia gravis		
	O Congenital Myasthenic Syndromes		
Myotonic Dystrophies	O Charcot-Marie Tooth and related neuropathies (HNNP, HSAN, dHMN)		
Other Muscular Dystrophies (excluding Duchenne, Becker, FSHD, myotonic dystrophie	Hereditary Amyloid Neuropathy		
Metabolic Myopathies	 Neuropathies associated with haematological disease and monoclonal gammopathy (MGUS, POEMS, ETC) Inflammatory and Dysimmune Neuropathies 		
O Idiopathic Inflammatory Myopathies			
Myofibrillar Myopathies	○ Small Fibre Neuropathies		
O Congenital Myopathies and Congenital muscular dystrophies	Idiopathic NeuropathiesI do not know the name of my disease		
Skeletal Muscle Channelopathies			
	Other		

PRELIMINARY DATA: Prevalent conditions


Answer Choices	%
Mitochondrial Diseases	18
Duchenne or Becker Muscular Dystrophy	4
Facioscapulohumeral Muscular Dystrophy (FSHD)	6
Myotonic Dystrophies	4
Other Muscular Dystrophies (excluding Duchenne, Becker, FSHD, myotonic dystrop	6
Metabolic Myopathies	2
Idiopathic Inflammatory Myopathies	3
Myofibrillar Myopathies	0
Congenital Myopathies and Congenital muscular dystrophies	2
Skeletal Muscle Channelopathies	0
Amyotrophic Lateral Sclerosis and other motor neuron diseases (excluding SMA)	1
Spinal Muscular Atrophy (SMA)	7
Myasthenia gravis	4
Congenital Myasthenic Syndromes	1
Charcot-Marie Tooth and related neuropathies (HNNP, HSAN, dHMN)	25
Hereditary Amyloid Neuropathy	0
Neuropathies associated with haematological disease and monoclonal gammopathy (0
Inflammatory and Dysimmune Neuropathies	1
Small Fibre Neuropathies	2
Idiopathic Neuropathies	1
I do not know the name of my disease	2
Other	12


- Charcot-Marie Tooth (25%)
- Mitochondrial diseases (18%)
- o SMA
- o FSHD
- Other dystrophies

Confidential data

Mancuso et al, submitted to OJRD, under review

Demographic data






Nation

Confidential data

Symptoms quantification:

severity scale




Confidential data

Mancuso et al, submitted to OJRD, under review.

Symptoms quantification:

MDCA severity score



Confidential data


Mancuso et al, submitted to OJRD, under review.

PROMMY APP


- Patient activation
- Patient data sharing
- Security aspects
- Data Gathered by the Prommy App
 - > Self evaluation
 - » PROMS



The "Omics" Cascade



Digital Biomarker & Environmental Triggers for Pain, Fatigue or.....



Data Gathered by the Prommy App


- The Prommy app allows patients to periodically assess their health status in relation to their disease and its symptoms.
- This is achieved through two types of interactions: Self-Evaluations and PROMs.

Self-Evaluation

How do you feel today (at the installation and *weekly* pop-up, but also when needed/desired)



If sad.... What is the annoying symptom that makes you sad (multiple choices allowed)?



Muscle Fatigue Muscle Weakness Impaired physical function **Coordination and/or balar Muscle Stiffness Muscle Pain** Other

PROMs

- Every 6 months, the patient will receive a pop-up asking him/her to fill in disease-related PROMs and the new PROM (under development)
- Self evaluation and PROMs may be exported as PDF and share with the physician and the ERN EURO-NMD Clinical registry
- Under consideration: personal wallet for patients

Conclusions and future directions

- ✓ We have developed a robust questionnaire that allowed us to understand the 5 most critical symptoms in all neuromuscular diseases
- ✓ Developed PROMMY (in collaboration with Devitalia SRL): Data safety, Unilateral communication from Prommy to the Registry, easy to use
- Ready to be launched in both Android and iOS
- Multilanguage will follow (now set fo ENG and ITA)

8" ERN EURO-NMD ANNUAL MEETING

Essen University Hospital, Germany

5th - 7th March 2025

THANK YOU









Prof. Michalangelo Mancuso <u>michelangelo.mancuso@unipi.it</u> Neurology Unit University Hospital AOUP, Pisa




Manuela Lavorato, PhD
ERN EURO-NMD WP7
Project Manager
Neurology Unit
Ospedale Universitario di Pisa
ernnmd@ao-pisa.toscana.it

Grateful to FL & all patients and to the ERN ExeC













and all other patient associations involved in the project!